Ann: Q3 FY23 Quarterly Investor Presentation, page-4

Happy that Luke Reid gave a breakdown of quarterly sales. Lower than hoped for, the rollout is slower than expected but all good on the disclosure front. Looking forward to continual jumps in revenues over coming periods from the test kits. He talks about uptake by GPs as the leading indicator for sales. Not convinced about that as GP interest does not pay the bills.

Listening to the presentation now, LR does tend to manxplain a bit but clearly he is directing his presentations to first time lookers at Microba so fair enough.